ProQR Therapeutics reports Q4 net loss of $9.1M, missing estimates
ProQR Therapeutics (NASDAQ:PRQR), a Leiden, Netherlands-based clinical-stage biotechnology company developing RNA-based therapies for severe genetic rare diseases, on Thursday reported a net loss of $9.1 million for its fourth quarter ended December 31, 2025.
The company said it had a loss of 9 cents per share.
The results missed the average estimate of an 8-cent loss per share from three analysts surveyed by Zacks Investment Research.
Revenue for the period totaled $5.5 million, primarily from collaboration agreements and license-related income tied to its ophthalmology programs.
For the full year 2025, ProQR reported a net loss of $47.7 million, or 45 cents per share.
Revenue reached $18 million, reflecting contributions from ongoing partnerships and milestone payments as the company advanced its pipeline of intravitreal RNA therapies targeting inherited retinal diseases.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
